|Other Names||Keratin, type I cytoskeletal 13, Cytokeratin-13, CK-13, Keratin-13, K13, KRT13|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6707a was selected from the N-term region of human KRT13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Expressed in some epidermal sweat gland ducts (at protein level) and in exocervix, esophagus and placenta|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
KRT13 is a member of the keratin gene family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. Most of the type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. This type I cytokeratin is paired with keratin 4 and expressed in the suprabasal layers of non-cornified stratified epithelia. Mutations in its gene and keratin 4 have been associated with the autosomal dominant disorder White Sponge Nevus.
Sheng,S., Mol. Cell. Endocrinol. 296 (1-2), 1-9 (2008)
If you have any additional inquiries please email technical services at email@example.com.